{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T22:56:54Z","timestamp":1788217014390,"version":"build-2803163510"},"reference-count":99,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100007054","name":"Meso Scale Diagnostics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","nmcd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nutrition, Metabolism and Cardiovascular Diseases"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.numecd.2020.07.012","type":"journal-article","created":{"date-parts":[[2020,7,17]],"date-time":"2020-07-17T21:41:33Z","timestamp":1595022093000},"page":"1926-1936","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Management of type 2 diabetes for prevention of cardiovascular disease. An expert opinion of the Italian Diabetes Society"],"prefix":"10.1016","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3366-2321","authenticated-orcid":false,"given":"Raffaele","family":"Napoli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gloria","family":"Formoso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Piro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Targher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agostino","family":"Consoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Purrello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.numecd.2020.07.012_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40842-016-0039-3","article-title":"Diabetes and its drivers: the largest epidemic in human history?","volume":"3","author":"Zimmet","year":"2017","journal-title":"Clin Diabetes Endocrinol"},{"key":"10.1016\/j.numecd.2020.07.012_bib2","first-page":"786","article-title":"Modest growth seen in epilepsy market","volume":"39","author":"Gohil","year":"2014","journal-title":"P T"},{"key":"10.1016\/j.numecd.2020.07.012_bib3","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1007\/s00125-003-1116-6","article-title":"Mortality from heart disease in a cohort of 23,000 patients with insulin-treated diabetes","volume":"46","author":"Laing","year":"2003","journal-title":"Diabetologia"},{"key":"10.1016\/j.numecd.2020.07.012_bib4","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.2337\/dc06-1441","article-title":"The effect of intensive diabetes treatment on resting heart rate in type 1 diabetes: the Diabetes Control and Complications Trial\/Epidemiology of Diabetes Interventions and Complications study","volume":"30","author":"Paterson","year":"2007","journal-title":"Diabetes Care"},{"key":"10.1016\/j.numecd.2020.07.012_bib5","doi-asserted-by":"crossref","first-page":"917","DOI":"10.2337\/diacare.26.3.917","article-title":"Economic costs of diabetes in the US in 2002","volume":"26","author":"Hogan","year":"2003","journal-title":"Diabetes Care"},{"key":"10.1016\/j.numecd.2020.07.012_bib6","doi-asserted-by":"crossref","first-page":"653789","DOI":"10.1155\/2013\/653789","article-title":"Impact of diabetes on cardiovascular disease: an update","volume":"2013","author":"Matheus","year":"2013","journal-title":"Int J Hypertens"},{"key":"10.1016\/j.numecd.2020.07.012_bib7","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.numecd.2010.01.008","article-title":"Cardiovascular risk in women with diabetes. Nutrition, metabolism, and cardiovascular diseases","volume":"20","author":"Rivellese","year":"2010","journal-title":"Nutr Metabol Cardiovasc Dis"},{"key":"10.1016\/j.numecd.2020.07.012_bib8","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1093\/eurheartj\/ehy653","article-title":"Equalization of four cardiovascular risk algorithms after systematic recalibration: individual-participant meta-analysis of 86 prospective studies","volume":"40","author":"Pennells","year":"2019","journal-title":"Eur Heart J"},{"key":"10.1016\/j.numecd.2020.07.012_bib9","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1161\/01.CIR.89.5.2462","article-title":"A definition of initial, fatty streak, and intermediate lesions of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association","volume":"89","author":"Stary","year":"1994","journal-title":"Circulation"},{"key":"10.1016\/j.numecd.2020.07.012_bib10","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1038\/nrcardio.2014.123","article-title":"Exploring unknowns in cardiology","volume":"11","author":"Alfieri","year":"2014","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.numecd.2020.07.012_bib11","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1172\/JCI10583","article-title":"Cellular mechanisms of insulin resistance","volume":"106","author":"Shulman","year":"2000","journal-title":"J Clin Investig"},{"key":"10.1016\/j.numecd.2020.07.012_bib12","doi-asserted-by":"crossref","first-page":"S103","DOI":"10.2337\/dc19-S010","article-title":"10. Cardiovascular disease and risk management: standards of medical care in diabetes-2019","volume":"42","author":"American Diabetes A","year":"2019","journal-title":"Diabetes Care"},{"key":"10.1016\/j.numecd.2020.07.012_bib13","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.2337\/dc13-2357","article-title":"Cardiovascular risk profile in subjects with prediabetes and new-onset type 2 diabetes identified by HbA(1c) according to American Diabetes Association criteria","volume":"37","author":"Di Pino","year":"2014","journal-title":"Diabetes Care"},{"key":"10.1016\/j.numecd.2020.07.012_bib14","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1056\/NEJMoa1800256","article-title":"Risk factors, mortality, and cardiovascular outcomes in patients with type 2 diabetes","volume":"379","author":"Rawshani","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.numecd.2020.07.012_bib15","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1007\/s00125-009-1470-0","article-title":"Intensive glucose control and macrovascular outcomes in type 2 diabetes","volume":"52","author":"Turnbull","year":"2009","journal-title":"Diabetologia"},{"key":"10.1016\/j.numecd.2020.07.012_bib16","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1056\/NEJMoa022314","article-title":"Intensive diabetes therapy and carotid intima-media thickness in type 1 diabetes mellitus","volume":"348","author":"Nathan","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.numecd.2020.07.012_bib17","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.1056\/NEJMoa052187","article-title":"Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes","volume":"353","author":"Nathan","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.numecd.2020.07.012_bib18","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa0802743","article-title":"Effects of intensive glucose lowering in type 2 diabetes","volume":"358","author":"Gerstein","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.numecd.2020.07.012_bib19","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1056\/NEJMoa0802987","article-title":"Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes","volume":"358","author":"Patel","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.numecd.2020.07.012_bib20","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0140-6736(98)07019-6","article-title":"Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group","volume":"352","author":"Anonymous","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.numecd.2020.07.012_bib21","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1056\/NEJM199309303291401","article-title":"The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus","volume":"329","author":"Nathan","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1016\/j.numecd.2020.07.012_bib22","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1056\/NEJMoa0808431","article-title":"Glucose control and vascular complications in veterans with type 2 diabetes","volume":"360","author":"Duckworth","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.numecd.2020.07.012_bib23","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1056\/NEJMoa0806470","article-title":"10-year follow-up of intensive glucose control in type 2 diabetes","volume":"359","author":"Holman","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.numecd.2020.07.012_bib24","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1016\/S0140-6736(09)60697-8","article-title":"Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials","volume":"373","author":"Ray","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.numecd.2020.07.012_bib25","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1056\/NEJMoa1414266","article-title":"Follow-up of glycemic control and cardiovascular outcomes in type 2 diabetes","volume":"372","author":"Hayward","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.numecd.2020.07.012_bib26","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.2337\/dc12-0413","article-title":"Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"35","author":"Inzucchi","year":"2012","journal-title":"Diabetes Care"},{"key":"10.1016\/j.numecd.2020.07.012_bib27","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1056\/NEJMoa072761","article-title":"Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes","volume":"356","author":"Nissen","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.numecd.2020.07.012_bib28","doi-asserted-by":"crossref","first-page":"S86","DOI":"10.2337\/dc18-S009","article-title":"9. Cardiovascular disease and risk management: standards of medical care in diabetes-2018","volume":"41","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.numecd.2020.07.012_bib29","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa1008862","article-title":"Diabetes mellitus, fasting glucose, and risk of cause-specific death","volume":"364","author":"Rao Kondapally Seshasai","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.numecd.2020.07.012_bib30","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.beem.2016.06.001","article-title":"Managing hypertension in type 2 diabetes mellitus","volume":"30","author":"Horr","year":"2016","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"10.1016\/j.numecd.2020.07.012_bib31","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1056\/NEJMoa1212914","article-title":"Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes","volume":"369","author":"Look","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.numecd.2020.07.012_bib32","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/S2213-8587(16)30162-0","article-title":"Association of the magnitude of weight loss and changes in physical fitness with long-term cardiovascular disease outcomes in overweight or obese people with type 2 diabetes: a post-hoc analysis of the Look AHEAD randomised clinical trial","volume":"4","author":"Look","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.numecd.2020.07.012_bib33","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1056\/NEJMoa1001286","article-title":"Effects of intensive blood-pressure control in type 2 diabetes mellitus","volume":"362","author":"Cushman","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.numecd.2020.07.012_bib34","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/S0140-6736(07)61303-8","article-title":"Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial","volume":"370","author":"Patel","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.numecd.2020.07.012_bib35","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1056\/NEJMoa1511939","article-title":"A randomized trial of intensive versus standard blood-pressure control","volume":"373","author":"Wright","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.numecd.2020.07.012_bib36","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/S0140-6736(98)04311-6","article-title":"Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group","volume":"351","author":"Hansson","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.numecd.2020.07.012_bib37","doi-asserted-by":"crossref","first-page":"S111","DOI":"10.2337\/dc20-S010","article-title":"10. Cardiovascular disease and risk management: standards of medical care in diabetes-2020","volume":"43","year":"2020","journal-title":"Diabetes Care"},{"key":"10.1016\/j.numecd.2020.07.012_bib38","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.2337\/dc05-2415","article-title":"Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN)","volume":"29","author":"Knopp","year":"2006","journal-title":"Diabetes Care"},{"key":"10.1016\/j.numecd.2020.07.012_bib39","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0140-6736(04)16895-5","article-title":"Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial","volume":"364","author":"Colhoun","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.numecd.2020.07.012_bib40","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1093\/eurheartj\/ehz486","article-title":"2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD","volume":"41","author":"Cosentino","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.numecd.2020.07.012_bib41","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.numecd.2020.07.012_bib42","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1056\/NEJMoa021778","article-title":"Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes","volume":"348","author":"Gaede","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.numecd.2020.07.012_bib43","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1056\/NEJMoa0706245","article-title":"Effect of a multifactorial intervention on mortality in type 2 diabetes","volume":"358","author":"Gaede","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.numecd.2020.07.012_bib44","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s00125-019-05039-w","article-title":"2019 update to: management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"63","author":"Buse","year":"2020","journal-title":"Diabetologia"},{"key":"10.1016\/j.numecd.2020.07.012_bib45","doi-asserted-by":"crossref","first-page":"S98","DOI":"10.2337\/dc20-S009","article-title":"9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2020","volume":"43","year":"2020","journal-title":"Diabetes Care"},{"key":"10.1016\/j.numecd.2020.07.012_bib46","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/S0140-6736(98)07037-8","article-title":"Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group","volume":"352","author":"Anonymous","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.numecd.2020.07.012_bib47","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1007\/s00125-017-4337-9","article-title":"Impact of metformin on cardiovascular disease: a meta-analysis of randomised trials among people with type 2 diabetes","volume":"60","author":"Griffin","year":"2017","journal-title":"Diabetologia"},{"key":"10.1016\/j.numecd.2020.07.012_bib48","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/S2213-8587(19)30422-X","article-title":"Association of glucose-lowering medications with cardiovascular outcomes: an umbrella review and evidence map","volume":"8","author":"Zhu","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.numecd.2020.07.012_bib49","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1038\/ajg.2013.5","article-title":"Anti-diabetic medications and the risk of hepatocellular cancer: a systematic review and meta-analysis","volume":"108","author":"Singh","year":"2013","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.numecd.2020.07.012_bib50","article-title":"Metformin in the prevention of hepatocellular carcinoma in diabetic patients: a systematic review","author":"Cunha","year":"2019","journal-title":"Ann Hepatol"},{"key":"10.1016\/j.numecd.2020.07.012_bib51","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/S2213-8587(17)30317-0","article-title":"Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial","volume":"5","author":"Vaccaro","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.numecd.2020.07.012_bib52","article-title":"Effect of linagliptin vs glimepiride on major adverse cardiovascular outcomes in patients with type 2 diabetes: the CAROLINA randomized clinical trial","author":"Rosenstock","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.numecd.2020.07.012_bib53","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabet.2019.12.007","article-title":"Efficacy and safety of anti-hyperglycaemic drugs in patients with non-alcoholic fatty liver disease with or without diabetes: an updated systematic review of randomized controlled trials","author":"Mantovani","year":"2020","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.numecd.2020.07.012_bib54","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1177\/1479164118825376","article-title":"Pioglitazone: the forgotten, cost-effective cardioprotective drug for type 2 diabetes","volume":"16","author":"DeFronzo","year":"2019","journal-title":"Diabetes Vasc Dis Res"},{"key":"10.1016\/j.numecd.2020.07.012_bib55","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/S0140-6736(05)67528-9","article-title":"Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial in macroVascular Events): a randomised controlled trial","volume":"366","author":"Dormandy","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.numecd.2020.07.012_bib56","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1056\/NEJMoa1506930","article-title":"Pioglitazone after ischemic stroke or transient ischemic attack","volume":"374","author":"Kernan","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.numecd.2020.07.012_bib57","doi-asserted-by":"crossref","first-page":"S73","DOI":"10.2337\/dc18-S008","article-title":"8. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2018","volume":"41","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.numecd.2020.07.012_bib58","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.2337\/dci18-0033","article-title":"Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"41","author":"Davies","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.numecd.2020.07.012_bib59","first-page":"62","article-title":"Dipeptidyl peptidase-4 inhibitor development and post-authorisation programme for vildagliptin \u2013 clinical evidence for optimised management of chronic diseases beyond type 2 diabetes","volume":"13","author":"Strain","year":"2017","journal-title":"Eur Endocrinol"},{"key":"10.1016\/j.numecd.2020.07.012_bib60","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.peptides.2017.10.011","article-title":"Peptide degradation and the role of DPP-4 inhibitors in the treatment of type 2 diabetes","volume":"100","author":"Deacon","year":"2018","journal-title":"Peptides"},{"key":"10.1016\/j.numecd.2020.07.012_bib61","doi-asserted-by":"crossref","first-page":"45","DOI":"10.3389\/fendo.2019.00045","article-title":"Diabetes and aging: from treatment goals to pharmacologic therapy","volume":"10","author":"Longo","year":"2019","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.numecd.2020.07.012_bib62","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1001\/jama.2010.405","article-title":"Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes","volume":"303","author":"Phung","year":"2010","journal-title":"JAMA"},{"key":"10.1016\/j.numecd.2020.07.012_bib63","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s12020-013-0090-0","article-title":"Baseline glycemic parameters predict the hemoglobin A1c response to DPP-4 inhibitors: meta-regression analysis of 78 randomized controlled trials with 20,053 patients","volume":"46","author":"Esposito","year":"2014","journal-title":"Endocrine"},{"key":"10.1016\/j.numecd.2020.07.012_bib64","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s00592-018-1222-z","article-title":"The efficacy and safety of dipeptidyl peptidase-4 inhibitors for type 2 diabetes: a Bayesian network meta-analysis of 58 randomized controlled trials","volume":"56","author":"Ling","year":"2019","journal-title":"Acta Diabetol"},{"key":"10.1016\/j.numecd.2020.07.012_bib65","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1002\/dmrr.2482","article-title":"Head-to-head comparison of dipeptidyl peptidase-IV inhibitors and sulfonylureas \u2013 a meta-analysis from randomized clinical trials","volume":"30","author":"Zhang","year":"2014","journal-title":"Diabetes Metab Res Rev"},{"key":"10.1016\/j.numecd.2020.07.012_bib66","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.diabres.2015.05.025","article-title":"The efficacy and safety of DPP4 inhibitors compared to sulfonylureas as add-on therapy to metformin in patients with Type 2 diabetes: a systematic review and meta-analysis","volume":"109","author":"Mishriky","year":"2015","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.numecd.2020.07.012_bib67","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1007\/s13300-018-0452-y","article-title":"Comparative effectiveness of DPP-4 inhibitors versus sulfonylurea for the treatment of type 2 diabetes in routine clinical practice: a retrospective multicenter real-world study","volume":"9","author":"Fadini","year":"2018","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.numecd.2020.07.012_bib68","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1111\/ijcp.12252","article-title":"Effectiveness and tolerability of second-line therapy with vildagliptin vs. other oral agents in type 2 diabetes: a real-life worldwide observational study (EDGE)","volume":"67","author":"Mathieu","year":"2013","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.numecd.2020.07.012_bib69","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.numecd.2009.03.015","article-title":"Dipeptydil peptidase-4 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials","volume":"20","author":"Monami","year":"2010","journal-title":"Nutr Metabol Cardiovasc Dis"},{"key":"10.1016\/j.numecd.2020.07.012_bib70","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1080\/14740338.2019.1626823","article-title":"An update on the safety and efficacy of oral antidiabetic drugs: DPP-4 inhibitors and SGLT-2 inhibitors","volume":"18","author":"Lamos","year":"2019","journal-title":"Expet Opin Drug Saf"},{"key":"10.1016\/j.numecd.2020.07.012_bib71","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1007\/s00592-018-1271-3","article-title":"Ten years of experience with DPP-4 inhibitors for the treatment of type 2 diabetes mellitus","volume":"56","author":"Sesti","year":"2019","journal-title":"Acta Diabetol"},{"key":"10.1016\/j.numecd.2020.07.012_bib72","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1161\/CIRCULATIONAHA.117.028136","article-title":"Cardiovascular actions and clinical outcomes with glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors","volume":"136","author":"Nauck","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.numecd.2020.07.012_bib73","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1001\/jama.2018.18269","article-title":"Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: the CARMELINA randomized clinical trial","volume":"321","author":"Rosenstock","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.numecd.2020.07.012_bib74","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1161\/CIRCULATIONAHA.114.010389","article-title":"Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial","volume":"130","author":"Scirica","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.numecd.2020.07.012_bib75","article-title":"Association of second-line antidiabetic medications with cardiovascular events among insured adults with type 2 diabetes","volume":"1","author":"O'Brien","year":"2018","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.numecd.2020.07.012_bib76","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.2147\/DDDT.S50773","article-title":"Update on developments with SGLT2 inhibitors in the management of type 2 diabetes","volume":"8","author":"Nauck","year":"2014","journal-title":"Drug Des Dev Ther"},{"key":"10.1016\/j.numecd.2020.07.012_bib77","doi-asserted-by":"crossref","first-page":"262","DOI":"10.7326\/0003-4819-159-4-201308200-00007","article-title":"Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis","volume":"159","author":"Vasilakou","year":"2013","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.numecd.2020.07.012_bib78","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1146\/annurev-med-051013-110046","article-title":"The mechanisms and therapeutic potential of SGLT2 inhibitors in diabetes mellitus","volume":"66","author":"Vallon","year":"2015","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.numecd.2020.07.012_bib79","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1007\/s00125-018-4663-6","article-title":"Use of SGLT2 inhibitors in type 2 diabetes: weighing the risks and benefits","volume":"61","author":"Lupsa","year":"2018","journal-title":"Diabetologia"},{"key":"10.1016\/j.numecd.2020.07.012_bib80","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1111\/dom.12054","article-title":"Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise","volume":"15","author":"Stenlof","year":"2013","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.numecd.2020.07.012_bib81","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/S2213-8587(13)70084-6","article-title":"Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"1","author":"Roden","year":"2013","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.numecd.2020.07.012_bib82","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1111\/dom.12888","article-title":"Phase III, efficacy and safety study of ertugliflozin monotherapy in people with type 2 diabetes mellitus inadequately controlled with diet and exercise alone","volume":"19","author":"Terra","year":"2017","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.numecd.2020.07.012_bib83","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.2337\/dc10-0612","article-title":"Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial","volume":"33","author":"Ferrannini","year":"2010","journal-title":"Diabetes Care"},{"key":"10.1016\/j.numecd.2020.07.012_bib84","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/dom.13047","article-title":"Efficacy and safety of sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors as monotherapy or add-on to metformin in patients with type 2 diabetes mellitus: a systematic review and meta-analysis","volume":"20","author":"Wang","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.numecd.2020.07.012_bib85","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/S2213-8587(14)70120-2","article-title":"Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial","volume":"2","author":"Ridderstrale","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.numecd.2020.07.012_bib86","article-title":"Safety and efficiency of SGLT2 inhibitor combining with insulin in subjects with diabetes: systematic review and meta-analysis of randomized controlled trials","volume":"96","author":"Yang","year":"2017","journal-title":"Medicine"},{"key":"10.1016\/j.numecd.2020.07.012_bib87","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1007\/s13300-019-0657-8","article-title":"SGLT2 inhibitors: cardiovascular benefits beyond HbA1c-translating evidence into practice","volume":"10","author":"Ali","year":"2019","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.numecd.2020.07.012_bib88","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.numecd.2020.07.012_bib89","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.numecd.2020.07.012_bib90","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s12902-019-0387-y","article-title":"SGLT2 inhibitors in T2D and associated comorbidities \u2013 differentiating within the class","volume":"19","author":"Schernthaner","year":"2019","journal-title":"BMC Endocr Disord"},{"key":"10.1016\/j.numecd.2020.07.012_bib91","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.numecd.2020.07.012_bib92","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.numecd.2020.07.012_bib93","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1007\/s13300-017-0320-1","article-title":"SGLT2 inhibitors through the windows of EMPA-REG and CANVAS trials: a review","volume":"8","author":"Rastogi","year":"2017","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.numecd.2020.07.012_bib94","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.numecd.2020.07.012_bib95","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1111\/dom.12451","article-title":"Potential for combination of dipeptidyl peptidase-4 inhibitors and sodium-glucose co-transporter-2 inhibitors for the treatment of type 2 diabetes","volume":"17","author":"Sharma","year":"2015","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.numecd.2020.07.012_bib96","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1080\/14740338.2018.1497158","article-title":"The safety of DPP-4 inhibitor and SGLT2 inhibitor combination therapies","volume":"17","author":"Molina-Vega","year":"2018","journal-title":"Expet Opin Drug Saf"},{"key":"10.1016\/j.numecd.2020.07.012_bib97","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1111\/j.1463-1326.2008.00993.x","article-title":"Fixed-dose single tablet antidiabetic combinations","volume":"11","author":"Bailey","year":"2009","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.numecd.2020.07.012_bib98","first-page":"679","article-title":"Do we prescribe what patients prefer? Pilot study to assess patient preferences for medication regimen characteristics","volume":"6","author":"Witticke","year":"2012","journal-title":"Patient Prefer Adherence"},{"key":"10.1016\/j.numecd.2020.07.012_bib99","first-page":"71","article-title":"Oral antidiabetic medication adherence and glycemic control in managed care","volume":"14","author":"Rozenfeld","year":"2008","journal-title":"Am J Manag Care"}],"container-title":["Nutrition, Metabolism and Cardiovascular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939475320302878?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939475320302878?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T16:14:42Z","timestamp":1760544882000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939475320302878"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":99,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["S0939475320302878"],"URL":"https:\/\/doi.org\/10.1016\/j.numecd.2020.07.012","relation":{},"ISSN":["0939-4753"],"issn-type":[{"value":"0939-4753","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of type 2 diabetes for prevention of cardiovascular disease. An expert opinion of the Italian Diabetes Society","name":"articletitle","label":"Article Title"},{"value":"Nutrition, Metabolism and Cardiovascular Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.numecd.2020.07.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Italian Diabetes Society, the Italian Society for the Study of Atherosclerosis, the Italian Society of Human Nutrition and the Department of Clinical Medicine and Surgery, Federico II University. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}